Plenary Speakers
AusBiotech are pleased to announce the following speakers are currently confirmed to present at AusBiotech 2010:
- Mr James C. Greenwood, President and CEO, Biotechnology Industry Organization, Washington D.C., United States
- Dr David Nicholson, Senior Vice President, Worldwide Licensing and Knowledge Management, Merck Worldwide Laboratories, New Jersey, United States
- Dr Robert W. Armstrong, Vice President, Global External Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indiana, United States
- Professor Nadia Rosenthal, Director, Australian Regenerative Medicine Institute, Monash University
- Dr John W. Holaday, Managing Director and CEO, QRxPharma Limited
- Dr Bornadata Bain, Global Research and Analysis Director, Datamonitor Healthcare, United States
- Dr Daniel Pascheles, Vice President, Head Global Competitive Intelligence, Merck & Co., Inc., New Jersey, United States
Mr James C. Greenwood Dr David Nicholson Dr Robert W. Armstrong
Professor Nadia Rosenthal Dr John W Holaday Dr Bornadata Bain
Session Speakers
As they are confirmed over the coming months a list of AusBiotech 2010 speaker and profiles will be available here*. Note: speakers listed in alphabetical order.
- Dr Paul Ashton, President & Chief Executive Officer, pSivida Corp., United States
- Dr Andrew Baker, Partner, GBS Venture Partners
- Dr Ashley Bates, Head of R&D Alliances, Australia & New Zealand, GlaxoSmithKline
- Hershel Berry, Managing Partner, Blueprint Life Sciences, United States
- Dr Wayne Best, Managing Director, Epichem Pty Ltd
- Dr Arun Bhatt, President, Clininvent Pvt Ltd, India
- Mr Swapan Bhattacharya, Managing Director, TCG Life Sciences, India
- Warren Bingham, President - Australia / New Zealand, Given Imaging Pty Ltd
- David Blake, Co Founder and Co Editor, BioShares
- Mel Bridges, Chairman and Company Director
- Lawrence Bremner, Managing Director, The Big Well
- Dr Chaline Brown, Senior Director Clinical Affairs, Ground Zero Pharmaceuticals Ltd, California, United States
- Dr Andrew Campitelli, Diagnostics Manager, MiniFAB (Aust) Pty Ltd
- Dr Jason Chaffey, Chief Technology Officer, bluechiip Pty Ltd
- Sue Charles, Managing Partner, College Hill Life Sciences, London, United Kingdom
- Dr Hiram Chipperfield, Consultant, ERA Consulting
- Dr Julian Clark, Head of Business Development, Walter and Eliza Hall Institute
- Robin Coleman, Principal, PharmBio Deals
- Dr Greg Collier, Chief Executive Officer and Managing Director, ChemGenex Pharmaceuticals
- Tony Conaghan, Lead Partner, Intellectual Property & Technology Practice, DLA Phillips Fox – Australia
- Jeremy Curnock – Cook, Managing Director, IB Fund Pty Ltd
- Glenn Cross, Chief Operating Officer, AusBiotech Ltd
- Dr Andrew Cuthbertson, Director of Research and Development and Chief Scientific Officer, CSL Limited
- Todd C. Davis, Co-Founder & Managing Director, Cowen Healthcare Royalty Partners, United States
- Dr Charlie Day, Chief Executive Officer, Melbourne Ventures
- Judy Develin, Coordinator, Market Authorisation Group, Therapeutic Goods Administration
- Professor Rocky De Nys, Head of Aquaculture, James Cook University
- Dr Alistair Draffan, Director Drug Discovery, Biota Holdings Limited
- Dr Ken Draper, Senior Director, Scientific Operations, LAB Research Inc., Canada
- Dr James Dromey, Business Development Manager, Walter and Eliza Hall Institute
- Steve Edelson, Executive Editor, SciBX, BioCentury, United States
- Geraldine Farrell, Special Counsel, Griffith Hack Lawyers
- Dr Leigh Farrell, VP Business Development, Biota Holdings Ltd
- Dr Gabby Fennessy, Manager, Policy and Strategy, Research Australia
- Dr David Fisher, Managing Director, Brandon Capital
- Ian Fitzpatrick, Manager Manufacturing Innovation Group, Invetech Pty Ltd
- Christopher Fugelsang, Tavistock Life Sciences, United States
- Dr Joshua Funder, GBS Venture Partners
- Andrew Gaffney, Partner, Middletons
- Nick Gatsios, Managing Director & Executive Director (Australia), HealthLinx
- Alex Gosman, Principal, Alex Gosman Consulting
- Lawrence Gozlan, Chief Executive Officer, Scientia Capital
- Dr Dianne Glenn, Principal, Corelli Consulting
- Dr Frank Grams, Executive Director, Roche Partnering Asia, Shanghai, China
- Dr Daniel Grant, Director, Asia R&D Business Development, Pfizer Australia
- Professor Sean Grimmond, Director, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland
- Dr Nicholas Gruen, Chief Executive Officer, Lateral Economics
- Ben Gust, Investment Manager, GBS Venture Partners
- Dr Rudolf Gygax, Managing Partner, Nextech Venture Ltd, Switzerland
- Lusia Guthrie, Chief Executive Officer & Managing Director, LBT Innovations Ltd
- Dr Lisa Haile, Partner Life Sciences Practice, DLA Piper - United States
- Karl Handelsman, Managing Director, CMEA Capital, United States
- Associate Professor Ben Hankamer, Director of the Solar Biofuels Consortium, Division of Chemistry and Structural Biology, The Institute for Molecular Bioscience
- Dr Suzanne Hasthorpe, Manager, Coordinating Office for Human Research Ethics, Victoria
- Dr David Haylock, Associate Professor Research Scientist, Materials Science and Engineering, CSIRO
- Anthony Honeyfield, Design Director, Design+Industry
- Josh Hexter, Executive Director, In-Licensing, BioLineRx Ltd, Israel
- Dr TJ Higgins, Honorary Fellow, CSIRO Plant Industry
- Dr Julia Hill, Director, Mantrax Ventures
- Dr Carrie Hillyard, Partner, CM Capital
- Dr Michael Hirshorn, Director, Four Hats Capital
- Peter Hobman, General Manager, MG Nutritionals Ltd
- Peter Howard, Partner, Middletons
- Dr Dianne Jackson-Matthews, Director, ERA Consulting (Australia) Pty Ltd
- Rebecca James, Chief Executive, Research Australia
- Andy Jane, Partner, CM Capital
- Bruce Jenett, Partner Life Sciences Practice, DLA Piper - United States
- Sue Jenkins-Marsh, Principal Project Officer, Queensland Health
- Amanda Jones, Principal, Watermark Trademark & Patent Attorneys
- Bill Karanatsios, Client Relationship Manager, Public Healthcare and Medical Research, Victorian Managed Insurance Authority
- Dr Phil Kearney, Director, Licensing & External Research, Merck & Co
- Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand
- Dr Kilian Kelly, Director Regulatory and Clinical, Mesoblast Limited
- Karen King, President, DSM Biologics, Germany
- Mitch Kirkman, Manager- Process, Training and Quality, International Clinical Operations and Oncology General Monitoring Organisation, Novartis
- Dr Gabriel Kremmidiotis, Vice President Discovery Research, Bionomics Limited
- Dr Jens Kroemer, Australian Institute for Bioengineering & Nanotechnology, The University of Queensland
- Dr Valentia Lee-Brotherton, Director, Toxicology, Ashuren Health Sciences, Canada
- Joe Lederman, Managing Principal, FoodLegal
- Dr David Lester, Director, Health Strategy and Coordination Group, CSIRO
- Peter Lewis, General Manager Business Development, Hydrix
- Michael Lusis, Business Director, Wilson HTM Corporate Finance
- Dr William Lyons, Vice President and General Manager, Boeing Research & Technology Australia
- Andrew Lysikatos, Chief Executive Officer, Axxin
- Luke Martin, Business Manager, Design+Industry
- Dr Scott Martin, Leader, Biomedical Manufacturing Research Theme, CSIRO
- Dr Sunil Mehta, Director Technology Development, KBI Biopharma Inc., North Carolina, United States
- Dr Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance, Toronto, Canada
- Graeme McRae, Chief Executive Officer, Bioniche Life Sciences, Canada
- Dr Jo Mitchell, Associate Director Research, Ethics and Public Health Training, NSW Health
- Peter Molloy, President, Aquarius Consulting, United States
- Dr Dean Moss, General Manager Life Sciences, UniQuest
- David Mulcahy, Vice President Product Development, ResMed Ltd
- Dr Lee Ann Murphy, Executive Director, Manitoba Agri Health Research Network, Manitoba, Canada
- Oleg Nodelman, Portfolio Manager / Partner, Biotechnology Value Fund, United States
- Dr Tania Obranovich, Partner, Davies Collison Cave
- Brad O'Connor, Chief Executive Officer, CogState Limited
- Doug Onsi, Managing Director, Healthcare Ventures, United States
- Fiona Pak Poy, General Partner, Innovation Capital
- Adam Panarello, Engineering Projects Manager (Hardware), TeleMedCare Pty Ltd
- Nicholas Peace, Investment Director, Starfish Ventures Pty Ltd
- Dr Axel Polack, General Partner, TVM Capital GmbH, Germany
- Dr Pamela Pollock, Vice Chancellor Senior Research Fellow, Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology
- Dr Susan Pond AM, Professor, Dow Sustainability Program, United States Studies Centre
- Professor Emeritus Ingo Potrykus, Chairman, Humanitarian Gloden Rice Board & Network, Switzerland
- Michael Quinn, Managing Partner, Innovation Capital
- Dr Ann Roberts, Project Manager,Plantic Technologies Ltd
- Peter Roberts, Senior Writer, The Australian Financial Review
- Craig Rogers, Chief Commercial Officer, Nucleus Network
- Dr Greg Roger, Chief Executive Officer, Advance Surgical Design & Manufacture Limited
- Hathaway Russell, Patent Attorney, Foley Hoag LLP, United States
- Alek Safarian, Chief Executive Officer, Novotech
- Peter Sandbach, Head of Communications, Roche Partnering, F. Hoffmann-La Roche AG, Switzerland
- Dr Lewis Schulz, Chief Operating Officer, Hatchtech Pty Ltd
- Dr Matthias Schuster, Scientific Director, Dx Assays, Singapore
- Rajeev Shah, Partner, RA Capital Management LLC ,United States
- Karen Sinclair, Principal, Watermark Patent & Trade Marks Attorneys, and President, Licensing Executives Society of Australia and New Zealand, Inc.
- Jayson Slotnik, Counsel, Foley Hoag LLP, Washington DC, United States
- Dr Pete Smith, Chief Executive Officer, Alchemia Limited
- Professor German Spangenberg, Executive Director Bioscience Research Division, Department of Primary Industries & Professor, Plant Genetics and Genomics, LaTrobe University
- Tom Stamp, Director, Blue Curve, Pty Ltd
- Dr Christopher Stewart, Director Asia Pacific Business Affairs & Director Sales, MPI Research, United States
- Dr Shane Story, Analyst Healthcare and Biotechnology, Wilson HTM Investment Group
- Margaret Stuart, Director, Margaret Stuart and Associates
- Professor Geoff Symonds, Chief Scientific Officer, Calimmune Australia
- Assoc Professor David Thomas, Medical Oncologist, Head Sarcoma, Peter Mac Callum Cancer Centre
- Megan Thomas, Research Manager, Jamieson Laboratories, Ontario, Canada
- Dr Mervyn Thomas, Bioinformatics and Regulatory Affairs Director, Althomics Pty Ltd
- Associate Professor Rob Thomas, Acting Chief Aquatic Sciences, South Australian Research and Development Institute
- Ian Thompson, General Manager, Amgen Australia Pty Ltd
- Malcolm Thompson, La Jolle Cove Investors, United States
- Dr Michael Thurn, Chief Executive Officer, Mimetica Pty Ltd
- Dr Richard Treagus, Chief Executive Officer, Acrux Ltd
- Dr Simon Tucker, Vice President Research, Biota Holdings Limited
- Dr Stewart Washer, Investment Manager, IB Managers
- Dr Chris Wahl, Director Business Development, Micropharma, Canada
- Dr Fintan Walton, Founder and Chief Executive Officer, PharmaVentures, United Kingdom
- Dr Christine Wichems, Medical Communications Manager, CSL Limited
- Nick Woolf, Non Executive Director, Phylogica Limited
- Associate Professor Karen Woolley, CEO, ProScribe Medical Communications
- Dr Stella Xu, Executive Director, Roche Partnering Asia, Shanghai, China
- Michele Yelmene, Regulatory Affairs & Quality Assurance Advisor to Industry, California, United States
*Speaker list current as at 14 October 2010
